Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis

Kaste, Sue C.; Pratt, Charles B.; Cain, Alvida M.; Jones-Wallace, Dana; Rao, Bhaskar N.

doi:10.1002/(sici)1097-0142(19991015)86:8<1602::aid-cncr31>3.0.co;2-r

Cited by 192 publications

(125 citation statements)

References 18 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Further genomic studies may explore this hy- pothesis. Similar to the findings from other studies, 7,6,22 the current results confirmed that complete excision of all metastatic sites carries a better prognosis. The prognostic value of resectability of all metastatic sites probably also is linked to the sensitivity of the disease to chemotherapy.…”

Section: Discussionsupporting

confidence: 91%

Metastatic osteosarcoma at diagnosis

Mialou

Philip

Kalifa

et al. 2005

Cancer

237

View full text Add to dashboard Cite

Blends of polypropylene (PP) and thermoplastic elastomers (TPE), namely SBS (styrene‐butadiene‐styrene) and SEBS (styrene‐ethylene/1‐butene‐styrene) block copolymers, were prepared to evaluate the effectiveness of the TPE type as an impact modifier for PP and influence of the concentration of elastomer on the polymer properties. Polypropylene homopolymer (PP‐H) and ethylene–propylene random copolymer (PP‐R) were evaluated as the PP matrix. Results showed that TPEs had a nucleating effect that caused the PP crystallization temperature to increase, with SBS being more effective than SEBS. Microstructure characterization tests showed that in most cases PP/SEBS blends showed the smallest rubber droplets regardless of the matrix used. It was seen that SEBS is a more effective toughening agent for PP than SBS. At 0°C the Izod impact strength of the PP‐H/SEBS 30% b/w blend was twofold higher than the SBS strength, with the PP‐R/SEBS 30% b/w blend showing no break. A similar behavior on tensile properties and flexural modulus were observed in both PP/TPE blends. Yield stress and tensile strength decreased and elongation at break increased by expanding the dispersed elastomeric phase in the PP matrix. © 2004 Wiley Periodicals, Inc. J Appl Polym Sci 95: 254–263, 2005

show abstract

Section: Discussionsupporting

confidence: 91%

Metastatic osteosarcoma at diagnosis

Mialou

Philip

Kalifa

et al. 2005

Cancer

237

View full text Add to dashboard Cite

show abstract

“…It is characterized by cells with OS differentiation, poorly defined borders, and cortical destruction that results in bone pain and compromised structural integrity (Luetke et al, 2014). Approximately 30% of the patients with OS present clinically detectable metastatic disease at diagnosis (Kaste et al, 1999;Kager et al, 2003). So far, researchers have not thoroughly investigated treatment methods that could significantly increase survival, excluding preoperative chemotherapy (Buddingh et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Identification of key biomarkers involved in osteosarcoma using altered modules

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. The aim of this study was to screen for key biomarkers of osteosarcoma (OS) by tracking altered modules. Protein-protein interaction (PPI) networks of OS and normal groups were constructed and re-weighted using the Pearson correlation coefficient (PCC), respectively. The condition-specific modules were explored from OS and normal PPI networks using a clique-merging algorithm. Altered modules were identified by a maximum weight bipartite-matching method. The important biological pathways in OS were identified by a pathway-enrichment analysis using genes from disrupted modules. The most important genes in these pathways were selected as key biomarkers. Finally, the mRNA and protein expressions of hub genes in OS bone tissues were analyzed using reverse transcription-polymerase chain reaction and western blotting, respectively. We identified 703 and 2270 modules in normal and disease networks, respectively; 150 altered modules were identified from among these and explored. We identified 10 important pathways based on gene pairs with altered PCC > 1 in the disrupted modules (P < 0.01), and PCNA, ATP6V1C2, ATP6V1G3, FEN1, CDC7, and RPA3 (expressed in these pathways) were selected as key genes of OS. We observed that these genes (and the proteins they encoded) were differentially expressed between normal and OS samples (P < 0.01) (excluding ATP6V1C2, whose protein expression did not differ significantly). Therefore, we identified 5 gene signatures that may be potential biomarkers for the detection and effective therapy of OS.

show abstract

“…An estimated 15% to 20% of individuals with osteosarcoma have identifiable metastases at initial presentation [1][2][3] , and these patients have a far worse prognosis compared with patients with localized disease only 1,[3][4][5][6][7][8][9][10] . There is a paucity of data regarding clinical characteristics associated with a greater risk of distant metastatic disease at diagnosis 5 .…”

mentioning

confidence: 99%